Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.IRON · Entity 2273 | Director | June 18, 2026 | June 23, 2026 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17 | Direct | 6,212 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
SUPERNUS PHARMACEUTICALS, INC.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,277 |
Ending reported balance
After 2026-03-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-05 · Sale · Disposed 10,000 · Balance 28,159 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 2 · 2026-03-06 · Exercise / conversion · Acquired 7,905 · Balance 36,064 Row 3 · 2026-03-06 · Sale · Disposed 8,787 · Balance 27,277 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 7,905 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2025-08-11 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Disposition to issuer · Disposed 44,474 · Balance 0 F1: This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-07 · Disposition to issuer · Disposed 32,069 · Balance 0 F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-07 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 14,090 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.84 · Expires 2026-01-01 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Raptor Pharmaceutical Corp
Report date October 24, 2016 · Filed October 26, 2016
Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-10-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-24 · Other · Disposed 2,092 · Balance 8,330 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 8,330 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-25 · Disposition to issuer · Disposed 7,915 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 1, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,855 | Not disclosed Strike: $22.30 | Not disclosed |
DisclosureSEC source: 0001179110-20-010060 · edgar.xml · derivative · entry 4 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,207 | Not disclosed Strike: $17.20 | Not disclosed |
DisclosureSEC source: 0001179110-20-010060 · edgar.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $14.84 | Not disclosed |
DisclosureSEC source: 0001179110-20-010060 · edgar.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-01-01 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerCommon Stock | 14,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010060 · edgar.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 16:48 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001179110-20-008797 · edgar.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2020 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 16:48 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 10,000 | $33.00 | $330,000.00 |
DisclosureSEC source: 0001179110-20-008797 · edgar.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,090 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2020 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 16:48 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 10,000 | $14.84 | $148,400.00 |
DisclosureSEC source: 0001179110-20-008797 · edgar.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2020 Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 19:03 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001179110-20-008586 · edgar.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2020 Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 19:03 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001179110-20-008586 · edgar.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,090 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 19:03 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 10,000 | $14.84 | $148,400.00 |
DisclosureSEC source: 0001179110-20-008586 · edgar.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2020 Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 17:46 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.09 | $0.00 |
DisclosureSEC source: 0001179110-20-007756 · edgar.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,305 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024851 · a4.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,305 Underlying: Common Stock · 9,305 shares Expires 2030-02-21 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,211 | $23.99 | $125,011.89 |
DisclosureSEC source: 0001104659-20-024851 · a4.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,211 F1 · shares: Represents restricted stock unit component of the annual equity compensation to directors. These shares will be settled in common stock upon vesting, such vesting to occur on February 21, 2021. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 16:16 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Unit · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008024 · edgar.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F3 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 16:16 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008024 · edgar.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:16 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001179110-19-008024 · edgar.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:25 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,427 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-010797 · a4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 Underlying: Common Stock · 12,427 shares Expires 2029-02-22 Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 18:00 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008969 · edgar.xml · derivative · entry 4 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F5 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 18:00 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008969 · edgar.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 Underlying: Common Stock · 4,356 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 18:00 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 8,855 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001179110-18-008969 · edgar.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 18:00 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008969 · edgar.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,613 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-012890 · a4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,613 Underlying: Common Stock · 8,613 shares Expires 2028-02-23 Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:06 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001209191-17-059626 · doc4.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F3 · price: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F3 · derivative.exercise_date: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:06 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,069 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0001209191-17-059626 · doc4.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,069 shares Expires 2026-05-18 F2 · price: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F2 · derivative.exercise_date: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:06 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,474 | Not disclosed Strike: $4.85 | Not disclosed |
DisclosureSEC source: 0001209191-17-059626 · doc4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,474 shares Expires 2025-08-11 F1 · price: This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. F1 · derivative.exercise_date: This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:09 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009450 · edgar.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:09 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 11,207 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001179110-17-009450 · edgar.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gemayel's continued service to the Company. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039589 · a4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:32 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001209191-17-035842 · doc4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012172 · a4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:43 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerStock Option (right to buy) · Derivative | 7,915 | Not disclosed Strike: $5.22 | Not disclosed |
DisclosureSEC source: 0001140361-16-083654 · doc1.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,915 shares Expires 2026-04-15 F3 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:43 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerCommon Stock | 8,330 | $9.00 | $74,970.00 |
DisclosureSEC source: 0001140361-16-083654 · doc1.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 16:43 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | OtherCommon Stock | 2,092 | $9.00 | $18,828.00 |
DisclosureSEC source: 0001140361-16-083654 · doc1.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,330 F1 · kind: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.